Top Markets
Coin of the day
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
株式のランク #31255
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
株価
$0.39
時価総額
$13.79M
変化(1日)
-13.53%
変化(1年)
-68.80%
IL
取引 NeuroSense Therapeutics Ltd. (NRSN)

カテゴリー

NeuroSense Therapeutics Ltd.(NRSN)の配当利回りの履歴
NeuroSense Therapeutics Ltd.(銘柄コード: NRSN)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
NeuroSense Therapeutics Ltd.(NRSN)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)
企業 配当利回り
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.48%
BE